Recorded November 16, 2015

Sponsored by

Webinar Description:

To reduce early stage development costs and lower late-stage attrition rates, many biopharmaceutical companies are using transient gene expression (TGE) rather than stable cell lines in their preclinical work. The MaxCyte STX® Scalable Transfection System is designed to cost-effectively produce multiple grams of antibodies, bispecifics, and other recombinant proteins following a single transient transfection. In this webinar, data will be presented demonstrating the ability of the MaxCyte STX to produce antibody titers up to 2.7 g/L in CHO cells, enough to run multiple studies (mechanistic studies, formulation development and stability, large animal PK&PD, downstream process & purification development, structural analysis & crystallography, etc.) in parallel. Data from a comprehensive protein analysis (VCD, protein quantitation, SDS-PAGE, and N-glycan) on proteins from CHOZN® cells transfected on the MaxCyte STX and produced stably will be discussed.

Learning Objectives:

  • Gain a familiarity with scalable flow transfection
  • Learn how to generate large quantities of protein quickly in CHO cells
  • Understand data comparing protein quality in transiently and stably transfected CHO cells
  • Explore how far in the preclinical process transiently produced protein can be used


James BradyJames Brady, Ph.D, MBA.

Vice President of Technical Applications and Customer Support

MaxCyte, Inc.


James Brady, Ph.D., is Vice President of Technical Applications and Customer Support at MaxCyte, Inc., where he has worked since 2004. Prior to joining MaxCyte, Dr. Brady was a Senior Scientist at Genetic Therapy, Inc. (a Novartis subsidiary) and a Group Leader at MetaMorhpix, Inc. Dr. Brady earned a B.S. in Biology from the College of William and Mary and a Ph.D. in Genetics from Indiana University. He also received postdoctoral training in the National Eye Institute of the National Institutes of Health.

Henry GeorgeHenry George

B.S. R&D Manager, Cell Sciences and Development



Henry George is an R&D Manager for the CHOZN® Platform R&D team within the Cell Sciences and Development group at/SAFC/Sigma Aldrich where he has worked since 2001. Prior to joining Sigma, Henry was a Principal Scientist at the DuPont Pharmaceutical Company (now part of Bristol Myers Squibb) and a Senior Scientist with R&D Systems, Inc. Henry earned his B.S. degree in Biology from Southern Illinois University at Edwardsville, and did graduate work at St. Louis University